Sign In
Buy SDGR
$14.93
-0.0100 (-0.0669%)
At Close: Jun 03, 2026
Why Shares of Schrödinger Are Falling Thursday
08:17pm, Thursday, 03'rd Aug 2023
Second-quarter revenue was down 9% year over year. Schrödinger increased revenue guidance for software revenue but decreased it for drug discovery.
Schrodinger, Inc. (SDGR) Reports Q2 Loss, Misses Revenue Estimates
08:58pm, Wednesday, 02'nd Aug 2023
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.62 per share a year ago.
Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist
07:01am, Tuesday, 01'st Aug 2023
Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users.
Biotech & Healthcare Meet AI: Stocks Soar On Innovation Potential
09:06am, Friday, 28'th Jul 2023
But some stocks in the biotech category are rising for a reason that's more common with techs, such as chipmaker Nvidia Corp. NASDAQ: NVDA or Microsoft Corp. NASDAQ: MSFT, which has made a significant
3 Cutting-Edge Biotech Stocks That Are Riding the AI Wave Like None Other
10:07am, Friday, 21'st Jul 2023
Recursion Pharmaceuticals just got Nvidia on board with its vision of AI for R&D. Ginkgo Bioworks is pairing AI with laboratory robotics to streamline R&D, too.
Schrödinger to Announce Second Quarter 2023 Financial Results on August 2
08:30am, Wednesday, 19'th Jul 2023
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its second quarter 202
Better AI Biotech Stock: Schrödinger vs. Recursion Pharmaceuticals
10:00am, Tuesday, 18'th Jul 2023
Schrödinger and Recursion Pharmaceuticals use AI to improve drug development. Neither one has proven its business model to be viable yet.
This Artificial Intelligence Biotech Stock Is Crushing the Market, but Is It a Buy?
10:15am, Monday, 17'th Jul 2023
Schrödinger's stock is riding the surge of interest in AI. Its drug discovery software is already bringing in money.
Why These 3 Stocks Are the Best Ways to Play AI Right Now
12:27pm, Tuesday, 11'th Jul 2023
Goldman Sachs recently asserted “that AI adoption could boost productivity growth by 1.5 percentage points per year over a 10-year period.” The venerable firm's estimate shows how tremendously
DPST And BTO: Schrodinger's Regional Banks
06:14am, Tuesday, 27'th Jun 2023
Regional Banks have all the characteristics of Schrodinger's Cat. They appear phenomenally cheap on current earnings. They are dead in the water when you price in a reasonable cost of funds.
7 Stocks in Hot Water: Dump This Dead Weight as Costs Skyrocket
08:52pm, Wednesday, 21'st Jun 2023
Although a topic that arouses myriad emotions, targeting overvalued stocks to sell represents an important component of investing strategy. Since we're in the middle of baseball season, you can't alwa
Why Shares of Schrödinger Rose This Week
01:20pm, Friday, 16'th Jun 2023
Schrödinger focuses on drug discovery using an AI platform. The company has already helped bring two therapies to market.
3 Revolutionary Companies With Trillion-Dollar Potential
08:01pm, Wednesday, 14'th Jun 2023
Finding early-stage, revolutionary companies whose market capitalizations can reach $1 trillion can be very lucrative. Just look atAlphabet (NASDAQ: GOOG, NASDAQ: GOOGL ), Apple (NASDAQ: AAPL ), and
Schrodinger, Inc. (SDGR) Surges 6.6%: Is This an Indication of Further Gains?
10:27am, Wednesday, 14'th Jun 2023
Schrodinger, Inc. (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price in
3 Pharma Stocks That Will Boom Thanks to AI
03:24pm, Friday, 26'th May 2023
A Deloitte report about artificial intelligence (AI) in the life sciences puts it bluntly. Big data is the new currency for biopharma firms.
